{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:17:46Z","timestamp":1767853066204,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Major Scientific Research Instrument Development Project of NSFC","award":["21827812"],"award-info":[{"award-number":["21827812"]}]},{"name":"The Key R & D Project in Agriculture and Animal Husbandrys of Rongchang","award":["19255"],"award-info":[{"award-number":["19255"]}]},{"name":"Chongqing Agriculture Development Grant","award":["17406"],"award-info":[{"award-number":["17406"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10637-020-01033-x","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T23:48:46Z","timestamp":1605829726000},"page":"615-626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Generation of fully human anti-GPC3 antibodies with high-affinity recognition of GPC3 positive tumors"],"prefix":"10.1007","volume":"39","author":[{"given":"Lin","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qilin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoli","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuohua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0459-7145","authenticated-orcid":false,"given":"Jianhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangpeng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"issue":"7","key":"1033_CR1","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/19420862.2016.1212149","volume":"8","author":"A Frenzel","year":"2016","unstructured":"Frenzel A, Schirrmann T, Hust M (2016) Phage display-derived human antibodies in clinical development and therapy. mAbs 8(7):1177\u20131194. https:\/\/doi.org\/10.1080\/19420862.2016.1212149","journal-title":"mAbs"},{"issue":"2","key":"1033_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00005-014-0322-x","volume":"63","author":"M Bruggemann","year":"2015","unstructured":"Bruggemann M, Osborn MJ, Ma B, Hayre J, Avis S, Lundstrom B, Buelow R (2015) Human antibody production in transgenic animals. Arch Immunol Ther Exp 63(2):101\u2013108. https:\/\/doi.org\/10.1007\/s00005-014-0322-x","journal-title":"Arch Immunol Ther Exp"},{"issue":"8","key":"1033_CR3","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1097\/TP.0000000000001702","volume":"101","author":"M Bruggemann","year":"2017","unstructured":"Bruggemann M, Osborn MJ, Ma B, Buelow R (2017) Strategies to obtain diverse and specific human monoclonal antibodies from transgenic animals. Transplantation 101(8):1770\u20131776. https:\/\/doi.org\/10.1097\/TP.0000000000001702","journal-title":"Transplantation"},{"key":"1033_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fimmu.2018.00460","volume":"9","author":"WC Chen","year":"2018","unstructured":"Chen WC, Murawsky CM (2018) Strategies for generating diverse antibody repertoires using transgenic animals expressing human antibodies. Front Immunol 9:460. https:\/\/doi.org\/10.3389\/fimmu.2018.00460","journal-title":"Front Immunol"},{"issue":"5","key":"1033_CR5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/gb-2008-9-5-224","volume":"9","author":"J Filmus","year":"2008","unstructured":"Filmus J, Capurro M, Rast J (2008) Glypicans. Genome Biol 9(5):224. https:\/\/doi.org\/10.1186\/gb-2008-9-5-224","journal-title":"Genome Biol"},{"key":"1033_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/med.21455","volume":"38","author":"F Zhou","year":"2017","unstructured":"Zhou F, Shang W, Yu X, Tian J (2017) Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev 38:741\u2013767. https:\/\/doi.org\/10.1002\/med.21455","journal-title":"Med Res Rev"},{"issue":"7","key":"1033_CR7","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1158\/0008-5472.Can-03-2191","volume":"64","author":"Y Hippo","year":"2004","unstructured":"Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo T, Kodama T, Aburatani H (2004) Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 64(7):2418\u20132423. https:\/\/doi.org\/10.1158\/0008-5472.Can-03-2191","journal-title":"Cancer Res"},{"issue":"1","key":"1033_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s0016-5085(03)00689-9","volume":"125","author":"M Capurro","year":"2003","unstructured":"Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125(1):89\u201397. https:\/\/doi.org\/10.1016\/s0016-5085(03)00689-9","journal-title":"Gastroenterology"},{"issue":"3","key":"1033_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1349-7006.2003.tb01430.x","volume":"94","author":"YK Sung","year":"2003","unstructured":"Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, Kim JC, Kim M (2003) Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 94(3):259\u2013262","journal-title":"Cancer Sci"},{"issue":"6","key":"1033_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1309\/hcqwpwd50xhd2dw6","volume":"129","author":"D Baumhoer","year":"2008","unstructured":"Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM (2008) Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 129(6):899\u2013906. https:\/\/doi.org\/10.1309\/hcqwpwd50xhd2dw6","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"1033_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/carcin\/bgu245","volume":"36","author":"X Liu","year":"2015","unstructured":"Liu X, Wang SK, Zhang K, Zhang H, Pan Q, Liu Z, Pan H, Xue L, Yen Y, Chu PG (2015) Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers. Carcinogenesis 36(2):232\u2013242. https:\/\/doi.org\/10.1093\/carcin\/bgu245","journal-title":"Carcinogenesis"},{"key":"1033_CR12","doi-asserted-by":"publisher","unstructured":"Kinoshita Y, Tanaka S, Souzaki R, Miyoshi K, Kohashi K, Oda Y, Nakatsura T, Taguchi T (2015) Glypican 3 expression in\u00a0pediatric malignant solid tumors. Eur J Pediatr Surg 25(1):138\u2013144. https:\/\/doi.org\/10.1055\/s-0034-1393961","DOI":"10.1055\/s-0034-1393961"},{"issue":"11","key":"1033_CR13","first-page":"1333","volume":"23","author":"BV Iglesias","year":"2008","unstructured":"Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, Puricelli L, de Kier Joffe EB (2008) Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol 23(11):1333\u20131340","journal-title":"Histol Histopathol"},{"key":"1033_CR14","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","volume":"65","author":"MI Capurro","year":"2005","unstructured":"Capurro MI, Xiang Y-Y, Lobe C, Filmus J (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65:6245\u20136254","journal-title":"Cancer Res"},{"issue":"3","key":"1033_CR15","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1074\/jbc.M410090200","volume":"280","author":"HH Song","year":"2005","unstructured":"Song HH, Shi W, Xiang YY, Filmus J (2005) The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 280(3):2116\u20132125. https:\/\/doi.org\/10.1074\/jbc.M410090200","journal-title":"J Biol Chem"},{"issue":"Pt 7","key":"1033_CR16","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1242\/jcs.140871","volume":"127","author":"M Capurro","year":"2014","unstructured":"Capurro M, Martin T, Shi W, Filmus J (2014) Glypican-3 binds to frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci 127(Pt 7):1565\u20131575. https:\/\/doi.org\/10.1242\/jcs.140871","journal-title":"J Cell Sci"},{"key":"1033_CR17","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/hep.30646","volume":"70","author":"N Li","year":"2019","unstructured":"Li N, Wei L, Liu X, Bai H, Ye Y, Li D, Li N, Baxa U, Wang Q, Lv L, Chen Y, Feng M, Lee B, Gao W, Ho M (2019) A frizzled-like cysteine rich domain in glypican-3 mediates Wnt binding and regulates hepatocellular carcinoma tumor growth in mice. Hepatology. 70:1231\u20131245. https:\/\/doi.org\/10.1002\/hep.30646","journal-title":"Hepatology."},{"issue":"4","key":"1033_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ijc.10856","volume":"103","author":"Y Midorikawa","year":"2003","unstructured":"Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M, Aburatani H (2003) Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 103(4):455\u2013465. https:\/\/doi.org\/10.1002\/ijc.10856","journal-title":"Int J Cancer"},{"issue":"9","key":"1033_CR19","doi-asserted-by":"publisher","first-page":"e0137664","DOI":"10.1371\/journal.pone.0137664","volume":"10","author":"C-M Wong","year":"2015","unstructured":"Wong C-M, Gao W, Kim H, Ho M (2015) Human monoclonal antibody targeting the heparan sulfate chains of glypican-3 inhibits HGF-mediated migration and motility of hepatocellular carcinoma cells. PLoS One 10(9):e0137664. https:\/\/doi.org\/10.1371\/journal.pone.0137664","journal-title":"PLoS One"},{"issue":"24","key":"1033_CR20","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.4161\/cbt.8.24.9985","volume":"8","author":"H Takai","year":"2009","unstructured":"Takai H, Ashihara M, Ishiguro T, Terashima H, Watanabe T, Kato A, Suzuki M (2009) Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma. Cancer Biol Ther 8(24):2329\u20132338","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"1033_CR21","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3892\/ijo.2015.2827","volume":"46","author":"Y Wu","year":"2015","unstructured":"Wu Y, Liu H, Weng H, Zhang X, Li P, Fan CL, Li B, Dong PL, Li L, Dooley S, Ding HG (2015) Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. Int J Oncol 46(3):1275\u20131285. https:\/\/doi.org\/10.3892\/ijo.2015.2827","journal-title":"Int J Oncol"},{"issue":"23","key":"1033_CR22","doi-asserted-by":"publisher","first-page":"9832","DOI":"10.1158\/0008-5472.CAN-08-1973","volume":"68","author":"T Ishiguro","year":"2008","unstructured":"Ishiguro T, Sugimoto M, Kinoshita Y, Miyazaki Y, Nakano K, Tsunoda H, Sugo I, Ohizumi I, Aburatani H, Hamakubo T, Kodama T, Tsuchiya M, Yamada-Okabe H (2008) Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 68(23):9832\u20139838. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1973","journal-title":"Cancer Res"},{"issue":"5","key":"1033_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.4161\/mabs.20933","volume":"4","author":"Y Phung","year":"2012","unstructured":"Phung Y, Gao W, Man YG, Nagata S, Ho M (2012) High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. mAbs 4(5):592\u2013599. https:\/\/doi.org\/10.4161\/mabs.20933","journal-title":"mAbs"},{"issue":"10","key":"1033_CR24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1097\/CAD.0b013e32833f5d68","volume":"21","author":"K Nakano","year":"2010","unstructured":"Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I, Igawa T, Tsunoda H, Kinoshita Y, Habu K, Orita T, Tsuchiya M, Hattori K, Yamada-Okabe H (2010) Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anti-Cancer Drugs 21(10):907\u2013916. https:\/\/doi.org\/10.1097\/CAD.0b013e32833f5d68","journal-title":"Anti-Cancer Drugs"},{"key":"1033_CR25","doi-asserted-by":"publisher","first-page":"33878","DOI":"10.1038\/srep33878","volume":"6","author":"YF Zhang","year":"2016","unstructured":"Zhang YF, Ho M (2016) Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma. Sci Rep 6:33878. https:\/\/doi.org\/10.1038\/srep33878","journal-title":"Sci Rep"},{"issue":"12","key":"1033_CR26","doi-asserted-by":"publisher","first-page":"E1083","DOI":"10.1073\/pnas.1217868110","volume":"110","author":"M Feng","year":"2013","unstructured":"Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M (2013) Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci 110(12):E1083\u2013E1091. https:\/\/doi.org\/10.1073\/pnas.1217868110","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"1033_CR27","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1021\/acs.molpharmaceut.5b00132","volume":"12","author":"H Hanaoka","year":"2015","unstructured":"Hanaoka H, Nagaya T, Sato K, Nakamura Y, Watanabe R, Harada T, Gao W, Feng M, Phung Y, Kim I, Paik CH, Choyke PL, Ho M, Kobayashi H (2015) Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. Mol Pharm 12(6):2151\u20132157. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00132","journal-title":"Mol Pharm"},{"issue":"2","key":"1033_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","volume":"65","author":"GK Abou-Alfa","year":"2016","unstructured":"Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryoo BY, Minguez B, Tanaka T, Ohtomo T, Ukrainskyj S, Boisserie F, Rutman O, Chen YC, Xu C, Shochat E, Jukofsky L, Reis B, Chen G, Di Laurenzio L, Lee R, Yen CJ (2016) Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol 65(2):289\u2013295. https:\/\/doi.org\/10.1016\/j.jhep.2016.04.004","journal-title":"J Hepatol"},{"issue":"5","key":"1033_CR29","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1073\/pnas.1616408114","volume":"114","author":"T Jain","year":"2017","unstructured":"Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Baruah H, Gray LT, Krauland EM, Xu Y, Vasquez M, Wittrup KD (2017) Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A 114(5):944\u2013949. https:\/\/doi.org\/10.1073\/pnas.1616408114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1033_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-1-60761-849-2_5","volume":"691","author":"JA Ramos-Vara","year":"2011","unstructured":"Ramos-Vara JA (2011) Principles and methods of immunohistochemistry. Methods Mol Biol (Clifton, NJ) 691:83\u201396. https:\/\/doi.org\/10.1007\/978-1-60761-849-2_5","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"issue":"9","key":"1033_CR31","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/bjc.1996.563","volume":"74","author":"DM Barnes","year":"1996","unstructured":"Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD (1996) Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74(9):1445\u20131451. https:\/\/doi.org\/10.1038\/bjc.1996.563","journal-title":"Br J Cancer"},{"issue":"410","key":"1033_CR32","doi-asserted-by":"publisher","first-page":"eaal4291","DOI":"10.1126\/scitranslmed.aal4291","volume":"9","author":"T Ishiguro","year":"2017","unstructured":"Ishiguro T, Sano Y, S-i K, Kamata-Sakurai M, Kaneko A, Kinoshita Y, Shiraiwa H, Azuma Y, Tsunenari T, Kayukawa Y, Sonobe Y, Ono N, Sakata K, Fujii T, Miyazaki Y, Noguchi M, Endo M, Harada A, Frings W, Fujii E, Nanba E, Narita A, Sakamoto A, Wakabayashi T, Konishi H, Segawa H, Igawa T, Tsushima T, Mutoh H, Nishito Y, Takahashi M, Stewart L, ElGabry E, Kawabe Y, Ishigai M, Chiba S, Aoki M, Hattori K, Nezu J (2017) An anti\u2013glypican 3\/CD3 bispecific T cell\u2013redirecting antibody for treatment of solid tumors. Sci Transl Med 9(410):eaal4291. https:\/\/doi.org\/10.1126\/scitranslmed.aal4291","journal-title":"Sci Transl Med"},{"issue":"6","key":"1033_CR33","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.4161\/19420862.2014.975660","volume":"6","author":"MD Oberst","year":"2014","unstructured":"Oberst MD, Fuhrmann S, Mulgrew K, Amann M, Cheng L, Lutterbuese P, Richman L, Coats S, Baeuerle PA, Hammond SA (2014) CEA\/CD3 bispecific antibody MEDI-565\/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. mAbs 6(6):1571\u20131584. https:\/\/doi.org\/10.4161\/19420862.2014.975660","journal-title":"mAbs"},{"issue":"4","key":"1033_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.12665\/J144.Witcher","volume":"14","author":"DT Ho","year":"2016","unstructured":"Ho DT, Park JF, Ho DE, Nunez B, Bang J, Ni JHT (2016) Fucosylation of a therapeutic antibody: effects on antibody-dependent, cell-mediated cytotoxicity (ADCC) potency and efficacy. BioProcess International 14(4):30\u201338","journal-title":"BioProcess International"},{"key":"1033_CR35","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-18-1078","volume":"18","author":"J Wu","year":"2019","unstructured":"Wu J, Han D, Shi S, Zhang Q, Zheng G, Wei M, Han Y, Li G, Yang F, Jiao D, Xie P, Zhang L, Yang AG, Zhao A, Qin W, Wen W (2019) A novel fully human antibody targeting extracellular domain of PSMA inhibits tumor growth in prostate cancer. Mol Cancer Ther 18:1289\u20131301. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-1078","journal-title":"Mol Cancer Ther"},{"key":"1033_CR36","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3389\/fimmu.2016.00690","volume":"7","author":"Z Jiang","year":"2016","unstructured":"Jiang Z, Jiang X, Chen S, Lai Y, Wei X, Li B, Lin S, Wang S, Wu Q, Liang Q, Liu Q, Peng M, Yu F, Weng J, Du X, Pei D, Liu P, Yao Y, Xue P, Li P (2016) Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. Front Immunol 7:690. https:\/\/doi.org\/10.3389\/fimmu.2016.00690","journal-title":"Front Immunol"},{"key":"1033_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/hep.30326","volume":"70","author":"Y Fu","year":"2018","unstructured":"Fu Y, Urban DJ, Nani RR, Zhang Y-F, Li N, Fu H, Shah H, Gorka AP, Guha R, Chen L, Hall MD, Schnermann MJ, Ho M (2018) Glypican-3 specific antibody drug conjugates targeting hepatocellular carcinoma. Hepatology. 70:563\u2013576. https:\/\/doi.org\/10.1002\/hep.30326","journal-title":"Hepatology."},{"key":"1033_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fonc.2019.00248","volume":"9","author":"Y Shimizu","year":"2019","unstructured":"Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T (2019) Next-generation cancer immunotherapy targeting glypican-3. Front Oncol 9:248. https:\/\/doi.org\/10.3389\/fonc.2019.00248","journal-title":"Front Oncol"},{"key":"1033_CR39","doi-asserted-by":"publisher","unstructured":"Yu X, Li Y, Chen SW, Shi Y, Xu F (2015) Differential expression of glypican-3 (GPC3) in lung squamous cell carcinoma and lung\u00a0adenocarcinoma and its clinical significance. Genet Mol Res 14(3):10185\u201310192. https:\/\/doi.org\/10.4238\/2015.August.28.2","DOI":"10.4238\/2015.August.28.2"},{"issue":"6","key":"1033_CR40","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181147","volume":"39","author":"D Wang","year":"2019","unstructured":"Wang D, Gao Y, Zhang Y, Wang L, Chen G (2019) Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of beta-catenin expression in lung squamous cell carcinoma. Biosci Rep 39(6):BSR20181147. https:\/\/doi.org\/10.1042\/BSR20181147","journal-title":"Biosci Rep"},{"key":"1033_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fonc.2019.00108","volume":"9","author":"MV Ortiz","year":"2019","unstructured":"Ortiz MV, Roberts SS, Glade Bender J, Shukla N, Wexler LH (2019) Immunotherapeutic targeting of GPC3 in pediatric solid embryonal tumors. Front Oncol 9:108. https:\/\/doi.org\/10.3389\/fonc.2019.00108","journal-title":"Front Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-01033-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:00:26Z","timestamp":1678510826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-01033-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-01033-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All protocols performed in studies involving animals were approved by the Ethics Committee of Chongqing Academy of Animal Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The participant has consented to the submission of this report to the journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A provisional patent application that covers the fully human anti-GPC3 antibodies and its usage has been filed jointly by Chongqing Academy of Animal Sciences and Chongqing CAMAB Biotech Ltd.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}